scispace - formally typeset
J

Jessica R E Bridgen

Researcher at Lancaster University

Publications -  9
Citations -  1001

Jessica R E Bridgen is an academic researcher from Lancaster University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 802 citations.

Papers
More filters
Posted ContentDOI

Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions

TL;DR: Using a transmission model, a basic reproductive number is estimated for Wuhan coronavirus (2019-nCoV) and it is estimated that 58-76% of transmissions must be prevented to stop increasing.
Journal ArticleDOI

Novel coronavirus 2019-nCoV (COVID-19): early estimation of epidemiological parameters and epidemic size estimates

TL;DR: In this article, the authors used a transmission model to estimate a basic reproductive number of 3.11 (95% CI, 2.39-4.13), indicating that 58-76% of transmissions must be prevented to stop increasing.
Posted ContentDOI

COVID-19 in England: spatial patterns and regional outbreaks

TL;DR: A wide range of spatial heterogeneity in COVID-19 epidemic distribution and infection rate exists in England currently, and the model used in this analysis is phenomenological for ease and speed of principled parameter inference, without attempting to enforce "SIR"-type epidemic dynamics.
Journal ArticleDOI

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England

TL;DR: In this paper , the authors investigated the hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 ( n = 984,337) in a large cohort study in England.
Journal ArticleDOI

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England

TL;DR: It is suggested that the risk of hospital admission is similar between BA.1 and BA.2 cases treated with Sotrovimab in the community, and there are concerns that it has reduced efficacy to treat people with the B.1.2 sub-lineage of the Omicron variant.